December 21, 2024: Saxenda Added to GLP-1 Consolidated Litigation
48% discontinuation among weight loss GLP-1 users 33% discontinuation among diabetes GLP-1 users Discontinuation of GLP-1 therapy is associated with metabolic rebound, including weight regain, rising blood pressure, and worsening glycemic control, undermining both clinical outcomes and the value of initial investment
Shes noticed, and suddenly shes told me and others in our circle, I dont want to eat because Im watching my figure, or, I weigh too much. This experience has given Lakshmi unique insight both wariness and compassion into the current Ozempic craze
Protein helps with satiety and may work well with semaglutides effects on appetite control
These issues have caused pain and distress
A 'discount' on a $1,400 medication might bring the price down to $1,000 or maybe $900